Editorial: Chemical Design and Biomedical Applications of Disulfide-rich Peptides: Challenges and Opportunities
The last two decades have witnessed of a revolution within the peptide field. From being considered just biochemical tools to becoming a real alternative to both small molecules and biologics as drugs. Currently, there are more than 90 peptides in the market ranging from small di- or tripeptides to...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/254325 |
| Acceso en línea: | http://hdl.handle.net/10261/254325 |
| Access Level: | acceso abierto |
| Palabra clave: | Peptides Biomedical Applications |
| Sumario: | The last two decades have witnessed of a revolution within the peptide field. From being considered just biochemical tools to becoming a real alternative to both small molecules and biologics as drugs. Currently, there are more than 90 peptides in the market ranging from small di- or tripeptides to large peptides containing more than 30 and even 40 amino acids (Henninot et al., 2018; Al Shaer et al., 2020). Among the last arrivals into the market, ixazomib (Ninlar®), which is an N-acylated, C-boronic acid dipeptide approved by the Food and Drug Administration (FDA) in 2015 for the treatment of multiple myeloma, and macimorelin (Macrilen®), a small pseudopeptide formed by three residues, approved by FDA in 2016 for the treatment of adult growth hormone deficiency, are examples of the first group (Al Shaer et al., 2020). Adlyxin (lixisenatide®), a 44 amino acid peptide, authorized by the same agency in 2016 for the treatment of the diabetes, could exemplify the second group (Al Shaer et al., 2020). |
|---|